NA
VTGN icon

NewEdge Advisors’s VistaGen Therapeutics VTGN Stock Holding History

NewEdge Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-743
Closed -$47K – 1199
2021
Q1 		$47K Buy
743
+100
+16% +$6.67K ﹤0.01% 1017
2020
Q4 		$37K Buy
643
+243
+61% +$6.2K ﹤0.01% 964
2020
Q3 		$8K Buy
+400
New +$8.28K ﹤0.01% 921

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's VTGN Position: Q2 2021 in Review

NewEdge Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2021, closing a stake of 743 shares — an estimated $47K sold.

NewEdge Advisors first reported a position in VTGN in Q3 2020 and held it in 3 quarters. The position peaked at $47K in Q1 2021. 101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

  • NewEdge Advisors reported no remaining VistaGen Therapeutics position as of Q2 2021 after selling out during the quarter.
  • NewEdge Advisors sold 743 VistaGen Therapeutics shares in Q2 2021, an estimated $47K.
  • NewEdge Advisors first reported a position in VistaGen Therapeutics in Q3 2020 and held it in 3 quarters.
  • NewEdge Advisors's VistaGen Therapeutics position peaked at $47K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on NewEdge Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.